fexuprazan + atorvastatin

fexuprazan + atorvastatin is a combination of two pharmaceutical drugs: fexuprazan, a potassium-competitive acid blocker (P-CAB), and atorvastatin, a statin (HMG-CoA reductase inhibitor). Fexuprazan acts by reversibly inhibiting the gastric proton pump (H+/K+-ATPase) in parietal cells of the stomach, greatly reducing gastric acid secretion, and is employed for acid-related disorders like GERD[3]. Atorvastatin inhibits HMG-CoA reductase to reduce cholesterol synthesis in the liver and is used to treat hypercholesterolemia and prevent cardiovascular disease[5]. Fexuprazan is primarily metabolized in the liver via CYP3A4, and so is atorvastatin. Co-administration of potassium-competitive acid blockers with statins may alter the pharmacokinetics of statins, potentially increasing systemic exposure and risk of certain adverse effects[1][3]. There is no unique brand for the combination as of the current date.